[
  {
    "ts": null,
    "headline": "Cardinal Health Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Cardinal Health Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=658c6a24f451bda32f5629f5c0a0212341cdc0cad62fd36bb958f65f5b3fc626",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733850180,
      "headline": "Cardinal Health Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131947149,
      "image": "",
      "related": "CAH",
      "source": "MarketWatch",
      "summary": "Cardinal Health Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=658c6a24f451bda32f5629f5c0a0212341cdc0cad62fd36bb958f65f5b3fc626"
    }
  },
  {
    "ts": null,
    "headline": "ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife",
    "summary": "AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.",
    "url": "https://finnhub.io/api/news?id=a0bfaf36bc6eb4a56faa920a6524e9367b848add717b5e98bf04adc43e806732",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733847240,
      "headline": "ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife",
      "id": 131905177,
      "image": "https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.",
      "url": "https://finnhub.io/api/news?id=a0bfaf36bc6eb4a56faa920a6524e9367b848add717b5e98bf04adc43e806732"
    }
  },
  {
    "ts": null,
    "headline": "Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=6f35abbfd586e3f7148063ce6f4e8c3ea4821a3bcc383bb3ac581bca39b14cb6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733841611,
      "headline": "Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term",
      "id": 131904303,
      "image": "https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=6f35abbfd586e3f7148063ce6f4e8c3ea4821a3bcc383bb3ac581bca39b14cb6"
    }
  },
  {
    "ts": null,
    "headline": "Pioneer Balanced ESG Fund Q3 2024 Performance And Market Commentary",
    "summary": "Pioneer Balanced ESG Fundâs Class Y shares returned 4.09% in the third quarter, underperforming the Fundâs equity and fixed income benchmarks. Read more here.",
    "url": "https://finnhub.io/api/news?id=342ef00ffdf9360c3d2a739a17135c531918eea0645a9234bd618c6fc0d2e531",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733836140,
      "headline": "Pioneer Balanced ESG Fund Q3 2024 Performance And Market Commentary",
      "id": 131905014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401878862/image_1401878862.jpg?io=getty-c-w1536",
      "related": "CAH",
      "source": "SeekingAlpha",
      "summary": "Pioneer Balanced ESG Fundâs Class Y shares returned 4.09% in the third quarter, underperforming the Fundâs equity and fixed income benchmarks. Read more here.",
      "url": "https://finnhub.io/api/news?id=342ef00ffdf9360c3d2a739a17135c531918eea0645a9234bd618c6fc0d2e531"
    }
  }
]